Solidarity Therapeutics trial produced conclusive evidence on effectiveness of repurposed drugs for COVID-19
On Oct. 15, 2020, the World Health Organization (WHO) announced Interim that results from the Solidarity Therapeutics Trial,…
-
-
Entos announced spin-off company Aegis Life to support global vaccine commercialization
On Oct. 15, 2020, Entos Pharmaceuticals announces that its San Diego-based spinout company Aegis Life, will pursuing U.S….
-
Fred Hutch completed move-in of Lake Union Steam Plant
On Nov. 9, 2020, after more than two years of reconstruction efforts, scientists from the Fred Hutchinson Cancer…
-
University of Oxford scientists developed extremely rapid diagnostic test for Covid-19
On Oct. 15, 2020, scientists from the University of Oxford’s Department of Physics announced they had developed an…
-
Global tuberculosis progress at risk during COVID-19 pandemic
On Oct. 14, 2020, the World Health Organization (WHO) announced that prior to the COVID-19 pandemic, many countries…
-
America’s Top Young Scientist of 2020: 14-year-old researched spike protein of SARS-CoV-2 virus
On Oct. 14, 2020, 3M and Discovery Education announced they had named 14-year-old Anika Chebrolu from Frisco, Texas,…
-
Pfizer and BioNTech announced publication of phase 1 data on lead mRNA vaccine candidate against COVID-19
On Oct. 14, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from the Phase 1 portion of…
-
Brazilian Health Regulatory Agency authorized Sorrento’s phase 2 clinical trial of Abivertinib in COVID-19 patients
On Oct. 14, 2020, Sorrento Therapeutics announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed…
-
US DOD expanded collaboration with AstraZeneca to develop and manufacture an investigational mab to prevent COVID-19
On Oct. 14, 2020, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DOD)…
-
FDA approved first treatment for Ebola virus
On Oct. 14, 2020, the FDA approved Regeneron Pharmaceutical’s Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three…
-
WHO announced position on genetically modified mosquitoes
On Oct. 14, 2020, recognizing the urgent need for new tools to combat vector-borne diseases (VBDs), and in…
-
Vaxart announced positive hamster challenge study data for its oral COVID-19 vaccine
On Oct. 14, 2020, Vaxart announced that the FDA had completed its review of the Companyﾒs Investigational New…
-
Thermo Fisher announced plans to expand sterile filling capacity for therapies and vaccines with new facility in Singapore
On Oct. 14, 2020, Thermo Fisher Scientific announced plans to develop two new sterile filling lines in Singapore…
-
Tevogen Bio submitted IND for T cell treatment in COVID-19
On Oct. 14, 2020, Tevogen Bio announced that its Investigational New Drug (IND) application to develop a COVID-19…
-
Moderna received confirmation of eligibility for submission of MAA to the European Medicines Agency for COVID-19 vaccine
On Oct. 14, 2020, Moderna announced that it had received written confirmation from the European Medicines Agency (EMA)…
-
Regeneron’s antibody cocktail REGN-EB3 (Inmazeb) first FDA-approved treatment for Ebola (Zaire Ebolavirus)
On Oct. 14, 2020, Regeneron announced that the FDA had approved Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) for the…
-
Moderna announced initiation of rolling submission to Health Canada for mRNA vaccine against COVID-19
On Oct. 13, 2020, Moderna announced initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s…
-
Roche launched laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients
On Oct. 13, 2020, Roche announced that it intended to launch a high-volume SARS-CoV-2 Antigen test as an…
-
COVID-19 vaccine with Dynavaxﾒs CpG 1018 adjuvant received Taiwan government subsidy with first dosage
On Oct. 13, 2020, Medigen Vaccine Biologics (MVC) and Dynavax Technologies announced that MVC had obtained a Taiwan…
-
Mosquitoes’ taste for blood traced to four types of neurons
On Oct. 13, 2020, Howard Hughes Medical Institute Investigator Leslie Vosshall’s team at The Rockefeller University and colleagues…
-
DOD awarded $481 million to Cue Health to increase domestic production capacity of point-of-care testing
On Oct. 13, 2020, the Department of Defense (DOD), on behalf of the U.S. Department of Health and…
-
NIH-funded study linked adolescent brain differences to increased waist circumference
On Oct. 13, 2020, the National Institute on Drug Abuse (NIDA) and nine other institutes, all part of…
-
Eli Lilly paused trial of antibody drug Trump touted as COVID-19 ‘cure’ over safety concern
On Oct. 13, 2020, Eli Lilly announced that the government-sponsored clinical trial of its COVID-19 antibody treatment similar…
-
Apogenix advanced clinical development of CD95L inhibitor asunercept in European COVID-19 phase II trial
On Oct. 13, 2020, Apogenix announced that the first patient has been enrolled in the ASUNCTIS trial. The…
-
RedHill Biopharma announced partnerships to expand manufacturing for COVID-19 therapeutic candidate opaganib
On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to…
-
NIH study to identify promising COVID-19 treatments for larger clinical trials
On Oct. 13, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), launched a study designed to…
-
NeoGenomics expanded global footprint in pharma services with new clinical research laboratory in Suzhou, China
On Oct. 13, 2020, NeoGenomics announced plans to open a state-of-the-art research laboratory in China in association with…
-
New CAR T-Cell therapy approved and available at Roswell Park for lymphoma patients
On Oct. 13, 2020, Roswell Park Comprehensive Cancer Center announced that it had been approved to administer the…
-
Cue received $481 million award to expand domestic production capacity of molecular, point-of-care COVID-19 tests
On Oct. 13, 2020, Cue Health announced a $481 Million award from the Department of Defense (DOD), on…
-
Johnson & Johnson temporarily paused all dosing in Janssen COVID-19 vaccine candidate clinical trials
On Oct. 12, 2020, Johnson & Johnson announced temporarily paused further dosing in all our COVID-19 vaccine candidate…
